Oligomycin Complex |
Catalog No.GC16533
One-Click Copy Product Info
|
Oligomycin Complex는 Oligomycin A, B, C의 혼합물이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1404-19-9
Sample solution is provided at 25 µL, 10mM.
Oligomycin Complex는 Oligomycin A, B, C의 혼합물이다. Oligomycin은 Streptomyces amylase chromogenes에서 분리된 유사한 26개 구성원의 메크로라이드 항생제이다. Oligomycin은 항진균 활동, 산화적 인산화 억제 및 살충활동이 있다[1]. Oligomycin A는 ATP 합성효소의 양자 채널(F0 서브유닛)을 차단하여 미토콘드리아 산화 인산화 작용을 억제하고 ATP 합성을 억제한다. 게다가 이는 종양 세포에서 산화 인산화의 보상적 증가를 줄여 세포 당화혈색소 수준을 낮춘다[2-4]. Oligomycin B는 ATP 합성효소의 비선택적 억제제로 심근 이색의 경우 ATP고갈을 효과적으로 늦추게 한다. Oligomycin C는 미토콘드리아 F1F0-ATP 합성효소의 억제제로, 더 민감한 세포 사망을 유도하고 세포 사망 패턴을 사멸에서 괴사로 변경한다.
Oligomycin(0-50µg/ml; 24시간)은 HepG2 및 R-HepG2 세포에서 미토콘드리아 막의 탈극화 및 사이토크롬 C의 릴리즈를 유도한다[5]. Oligomycin A(0-16 µM; 12-48 시간)은 HT29 세포의 생존 및 증식을 촉진한다[6]. A549 세포에서 100 ng/ml Oligomycin은 1시간 내에 OXPHOS의 인산화활성을 완전하게 억제하고 다양한 수준의 당화 이득을 자극한다[7]. 5 µg/ml Oligomycin은 H+-ATP-synthetase의 F0 부분을 억제하고 TNF가 유도한 Hela 세포에서의 사이토크롬 C의 릴리즈 및 사멸을 강력하게 억제한다[8]. Oligomycin B(1 µM)은 황산염약물 수용체 2 null (SUR2(nl))에서 SUR2 wild-type (SUR2(wt)) 동맥보다 39-61% 작은 혈관 확장을 유도한다[9].
References:
[1]. SMITH RM, PETERSON WH, et,al.Oligomycin, a new antifungal antibiotic. Antibiot Chemother (Northfield). 1954 Sep;4(9):962-70. PMID: 24543225.
[2]. Vestergaard M, NØhr-Meldgaard K, et al. Inhibition of the ATP synthase eliminates the intrinsic resistance of Staphylococcus aureustowards polymyxins[J].mBio, 2017, 8(5): e01114-17.
[3]. Untereiner AA, Pavlidou A, et al. Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells[J].Biochem Pharmacol, 2018, 149: 174-185.
[4]. Ruas JS, Siqueira-Santos ES, et al. High glycolytic activity of tumor cells leads to underestimation of electron transport system capacity when mitochondrial ATP synthase is inhibited[J].Sci Rep, 2018, 8(1): 17383.
[5]. Li YC, Fung KP, et,al. Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62. doi: 10.1159/000077803. PMID: 15211078.
[6]. Li X, Tian R, et,al. Oligomycin A promotes radioresistance in HT29 colorectal cancer cells and its mechanisms. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Feb 28;46(2):113-120. English, Chinese. doi: 10.11817/j.issn.1672-7347.2021.200063. PMID: 33678646.
[7]. Hao W, Chang CP, et al. Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. J Biol Chem. 2010 Apr 23;285(17):12647-54. doi: 10.1074/jbc.M109.084194. Epub 2010 Jan 28. PMID: 20110356; PMCID: PMC2857128.
[8]. Shchepina LA, Pletjushkina OY, et al. Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis. Oncogene. 2002 Nov 21;21(53):8149-57. doi: 10.1038/sj.onc.1206053. PMID: 12444550.
[9]. Adebiyi A, McNally EM, et al. Vasodilation induced by oxygen/glucose deprivation is attenuated in cerebral arteries of SUR2 null mice. Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1360-8. doi: 10.1152/ajpheart.00406.2011. Epub 2011 Jul 22. PMID: 21784985; PMCID: PMC3197357.
| 세포 실험 [1]: | |
세포 라인 | R-HepG2 및HepG2 세포 |
제조 방법 | 세포는 37°C, 5% CO2 조건에서 지정된 농도로 Oligomycin으로 처리하거나 24시간 동안 미디엄 만 처리했습니다. |
반응 조건 | 0-50μg/ml; 24시간 동안 |
응용 분야 | Oligomycin은 R-HepG2 및 HepG2 세포의 미토콘드리아 탈극화를 유도합니다. |
| 동물 실험 [2]: | |
동물 모형 | HT29세포 |
제조 방법 | 세포는 12, 24, 36 및 48시간 동안 다양한 농도의 Oligomycin A로 배양되었습니다. |
제형 | 0-16 μM;12-48 시간 동안 |
응용 분야 | Oligomycin은 HT29 세포의 생존 및 증식을 촉진합니다. |
참고문헌: [1]. Li YC, Fung KP, et,al. Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62. doi: 10.1159/000077803. PMID: 15211078. [2]. Li X, Tian R, et,al. Oligomycin A promotes radioresistance in HT29 colorectal cancer cells and its mechanisms. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Feb 28;46(2):113-120. English, Chinese. doi: 10.11817/j.issn.1672-7347.2021.200063. PMID: 33678646. | |
| Cas No. | 1404-19-9 | SDF | |
| Canonical SMILES | O=C([C@H]([C@@H]([C@H](C([C@](C)([C@@H]([C@H](C/C=C/C=C/[C@]([H])(CC[C@@]1([C@@H]([C@]([H])(O2)[C@H]([C@@]3(O1)C(C[C@H]([C@]([H])(O3)C[C@H](C)O)C)=O)C)C)[H])CC)C)O)O)=O)C)O)C)[C@@H]([C@H]([C@@H](/C=C/C2=O)C)O)C.O=C([C@H]([C@@H]([C@H](C([C@](C)([C@@H]([C@H | ||
| Formula | C45H74O11 for Oligomycin A; C45H72O12 for Oligomycin B; C45H74O10 for Oligomycin C. | M.Wt | 791.06 for Oligomycin A; 805.1 for Oligomycin B; 775.1 for Oligomycin C. |
| Solubility | ≤30mg/ml in ethanol;20mg/ml in DMSO;30mg/ml in dimethyl formamide | Storage | Store at -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2641 mL | 6.3206 mL | 12.6413 mL |
| 5 mM | 252.8 μL | 1.2641 mL | 2.5283 mL |
| 10 mM | 126.4 μL | 632.1 μL | 1.2641 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)